Compare DCO & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCO | GPCR |
|---|---|---|
| Founded | 1849 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2023 |
| Metric | DCO | GPCR |
|---|---|---|
| Price | $95.85 | $68.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $117.80 | $97.90 |
| AVG Volume (30 Days) | 100.3K | ★ 2.4M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $806,224,000.00 | N/A |
| Revenue This Year | $6.11 | N/A |
| Revenue Next Year | $8.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.17 | N/A |
| 52 Week Low | $51.76 | $13.22 |
| 52 Week High | $101.47 | $94.90 |
| Indicator | DCO | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 68.61 |
| Support Level | $91.51 | $61.87 |
| Resistance Level | $99.23 | $72.00 |
| Average True Range (ATR) | 2.99 | 7.83 |
| MACD | 0.69 | 0.38 |
| Stochastic Oscillator | 78.17 | 48.10 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.